The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transpupillary thermotherapy for age-related macular degeneration in June 2004. In accordance with the Interventional Procedures Programme Process Guide, guidance on procedures with special arrangements are reviewed 3 years after publication and the procedure is reassessed if important new evidence is available.
The guidance was considered for reassessment in June 2007 and it was concluded that NICE will not be updating this guidance at this stage. However, if you believe there is new evidence which should warrant a review of our guidance, please contact us via the email address below.
Age-related macular degeneration is the commonest cause of irreversible blindness in developed countries. Transpupillary thermotherapy uses laser energy to coagulate vessels in the wet form of macular degeneration and is intended to alter the disease process and preserve vision.